Quick answers
- What is Naratriptan used for?
- The FDA-approved label (Naratriptan, Asclemed USA Inc., August 7, 2026) says: “Naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with naratriptan tablets reconsider the diagnosis of migraine before naratriptan tablets are administered to treat any subsequent attacks. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Naratriptan have a boxed warning?
- No. None of the 4 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Naratriptan?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Naratriptan been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Naratriptan?
- 4 companies list prescription products of Naratriptan in the FDA NDC Directory, including Bionpharma Inc., Asclemed USA, Inc. and Hikma Pharmaceuticals USA Inc..
What Naratriptan is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with naratriptan tablets reconsider the diagnosis of migraine before naratriptan tablets are administered to treat any subsequent attacks. …
— FDA label: Naratriptan, Asclemed USA Inc., effective August 7, 2026. Read the full label on DailyMed →
The FDA has 4 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 4 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet · Tablet, film coated |
|---|---|
| Route | Oral |
| Prescription products | 8 in the FDA NDC Directory |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| naratriptan hydrochloride 1 mg tablet | Generic | $1.72 per tablet |
| naratriptan hydrochloride 2.5 mg tablet | Generic | $1.10 per tablet |
| naratriptan hydrochloride 2.5 mg tablet, film coated | Generic | $1.10 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bionpharma Inc.2 products
- Asclemed USA, Inc.2 products
- Hikma Pharmaceuticals USA Inc.2 products
- Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.2 products
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (3)
- ANDA090381Hikma · July 7, 2010
- ANDA200502Heritage · February 28, 2011
- ANDA091441Orbion Pharms · April 30, 2012
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 311918, 314135 |
|---|---|
| SPL set ID of the quoted label | 63ea356f-0895-4540-b242-8e611eacd938 |
| FDA labels (SPL) | 4 |
| FDA applications | 3 ANDA |
| Active ingredients (FDA) | NARATRIPTAN |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Naratriptan, Asclemed USA Inc., effective August 7, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →